In particular, the immunomodulatory and anti-inflammatory responses of Bruton tyrosine kinase inhibitors (BTKi), and the potential risks of cytokine storm and hyperviscosity caused by BTKi withdrawal in worsening late complications of COVID-19 are highlighted. This evidence concerns the gene BTK and COVID-19.